State access

GLP-1 telehealth access by state

State access for GLP-1 telehealth is governed less by medication law than by prescriber licensure and pharmacy shipping rules. Here is what genuinely differs by state — interstate licensure compact membership — and an honest account of what we have not yet independently researched for each state.

What genuinely varies by state

• Licensure compact membership. 38 states/territories belong to both the Nurse Licensure Compact (NLC) and the Interstate Medical Licensure Compact (IMLC), which streamline multistate licensure for nurse practitioners and physicians respectively. Non-member states may have fewer telehealth clinicians able to prescribe to you quickly.
• Individual provider footprints. Not every telehealth company operates in every state, and pricing can differ by state even for the same company — see the reported exceptions below for two documented cases.
• Pharmacy nonresident registration. Compounding pharmacies must register as a nonresident pharmacy in most states before shipping to patients there; this is a real constraint on availability that we have not yet independently mapped per state.

What does not vary by state

Federal FDA approval status, drug labeling, and the underlying compounding rules under 21 U.S.C. §353a (Section 503A) are federal, not state, matters — they apply uniformly regardless of which state you live in. A provider cannot legally offer a materially different clinical justification for compounding in one state versus another; if a provider's marketing implies otherwise, treat that as a claim to verify independently, not as a documented state-law difference.

State-by-state compact membership

The table below is the complete, sourced dataset we have for all 50 states plus the District of Columbia. Every other field on a given state's page — prescriber availability, pharmacy shipping eligibility, state-specific restrictions — is currently Unverified — no source on file because it has not yet been individually researched; those state pages are marked noindex until that research is complete.

Reported provider exceptions

Across our provider-pricing dataset, exactly two states have a documented, provider-specific reported exception — both are provider-reported, not independently verified by us:

• California:
  • Oak Longevity: Compounded semaglutide programme is not available in California. Provider reported
  • bmiMD: California residents are charged $379.99 per month for compounded semaglutide against $289 elsewhere. Provider reported
• North Carolina:
  • bmiMD: North Carolina residents are charged $379.99 per month for compounded semaglutide against $289 elsewhere. Provider reported

What we have not verified

For every state, the following remain unresearched at this stage and are labeled Unverified — no source on file rather than guessed: whether a synchronous audio-visual visit is required before a first prescription, state-specific compounding advisories or restrictions on GLP-1 medications, the current nonresident-pharmacy registrant list, and each state's Medicaid coverage position for anti-obesity medication. Use the official board directories linked in the sources panel to check these directly rather than relying on any provider's marketing claim.